XL388,
XL388,
1251156-08-7,
XL-388,
XL 388,
CHEMBL2333365,
(7-(6-aminopyridin-3-yl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)(3-fluoro-2-methyl-4-(methylsulfonyl)phenyl)methanone,
[7-(6-aminopyridin-3-yl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone,
(7-(6-Amino-3-pyridinyl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl)(3-fluoro-2-methyl-4-(methylsulfonyl)phenyl)-methanone,
[7-(6-Amino-3-pyridinyl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methyl-4-(methylsulfonyl)phenyl]-methanone,
GTPL7973,
SCHEMBL3761352,
SYN1186,
LNFBAYSBVQBKFR-UHFFFAOYSA-N,
BCP07897,
EX-A1571,
2808AH,
BDBM50429867,
s7035,
ZINC95550928,
AKOS024458404,
CS-1535,
SB16471,
NCGC00351483-07,
4CA-0004,
AK471618,
AS-16320,
BC600467,
DA-46704,
HY-13806,
SC-95569,
FT-0738721,
A12395,
W-6030,
J-005199,
[7-(6-Aminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methyl-4-(methylsulfonyl)phenyl]methanone,
(-)-Catechin gallate,
D03BNU,
C23H22FN3O4S,
A3940,
MTORC1/mTORC2 inhibitors (oral, cancer), Exelixis,